, a biopharmaceutical company, engages in the discovery, development, and manufacture of biologics, particularly blood-related proteins.
It implements a separation process that uses affinity chromatography technology to recover valuable therapeutic proteins from human plasma.
The company develops a portfolio of protein-based therapeutics, such as oxygen therapeutics for the treatment of high volume blood loss; drug delivery therapeutics for the treatment of Hepatitis C and liver cancer; and cell therapeutics for the treatment of chronic myelogenous leukemia and chemotherapy-induced anemia.
It has a strategic alliance with ProMetic Biosciences, Ltd.
Hemosol is headquartered in Mississauga, Canada.
